Steven Gourlay

Title: The Innovations of Steven Gourlay

Introduction

Steven Gourlay is an accomplished inventor based in Queens Park, Australia. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of immune thrombocytopenia. His innovative work has led to the development of a unique patent that addresses this medical condition.

Latest Patents

Gourlay holds a patent for "Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile." This patent discloses methods for treating immune thrombocytopenia by administering at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) and pharmaceutically acceptable salts thereof. Additionally, pharmaceutical compositions comprising at least one compound chosen from PRN1008 and pharmaceutically acceptable salts are also disclosed.

Career Highlights

Gourlay is currently associated with Principia Biopharma Inc., where he continues to advance his research and development efforts. His work has been pivotal in creating effective treatments for patients suffering from immune thrombocytopenia.

Collaborations

Steven Gourlay collaborates with notable colleagues, including Ann Neale and Philip Nunn. Their combined expertise contributes to the innovative environment at Principia Biopharma Inc.

Conclusion

Steven Gourlay's contributions to the field of pharmaceuticals, particularly through his patent for treating immune thrombocytopenia, highlight his role as a significant inventor. His ongoing work at Principia Biopharma Inc. continues to pave the way for advancements in medical treatments.